Results 71 to 80 of about 16,733 (229)

In vitro selection of aztreonam/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae

Journal of Antimicrobial Chemotherapy, 2019
AbstractObjectivesTo examine the in vitro selection of aztreonam/avibactam resistance among MBL-producing Klebsiella pneumoniae and to understand the mechanism of increased resistance.MethodsThe MICs of aztreonam were determined with and without avibactam (4 mg/L) using a broth microdilution method.
Siqiang, Niu, Jie, Wei, Chunhong, Zou, Kalyan D, Chavda, Jingnan, Lv, Haifang, Zhang, Hong, Du, Yi-Wei, Tang, Johann D D, Pitout, Robert A, Bonomo, Barry N, Kreiswirth, Liang, Chen   +11 more
openaire   +3 more sources

Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria [PDF]

, 2021
BACKGROUND: Boronates are of growing interest as β-lactamase inhibitors. The only marketed analogue, vaborbactam, principally targets KPC carbapenemases, but taniborbactam (VNRX-5133, Venatorx) has a broader spectrum.
Doumith, Michel, Ellington, Matthew J., Livermore, David, Mushtaq, Shazad, Vickers, Anna, Woodford, Neil   +5 more
core   +1 more source

Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21)

JAC-Antimicrobial Resistance, 2023
Background Aztreonam/avibactam is under development to treat infections caused by Gram-negative bacteria. We evaluated the in vitro activities of aztreonam/avibactam and comparators against a global collection of carbapenem-resistant Enterobacterales ...
H. Sader, M. Castanheira, J. Kimbrough, Valerie Kantro, R. Mendes   +4 more
semanticscholar   +1 more source

EXTENSIVELY DRUG-RESISTANT \u3cem\u3ePSEUDOMONAS AERUGINOSA IN VITRO\u3c/em\u3e SUSCEPTIBILITY AND MECHANISMS OF RESISTANCE [PDF]

, 2020
Pseudomonas aeruginosa causes severe healthcare-associated infections. Forty-eight extensively drug-resistant (XDR)-P. aeruginosa isolates were selected from 287 isolates collected for evaluation based on clinical susceptibility data.
Gallagher, Chanah
core   +1 more source

Antimicrobal resistance of nosocomial carbapenemase-producing Enterobacterales in Russia: results of surveillance, 2014-2016 [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2018
Objective. To assess the prevalence and antimicrobial susceptibility of carbapenemase-producing Enterobacterales (CPE). Materials and Methods. A total of 5539 Enterobacterales isolates recovered from hospitalized patients in 52 medical institutions ...
Shajdullina E.R., Edelstein M.V., Skleenova E.Yu., Sukhorukova M.V., Kozlov R.S.   +4 more
doaj   +1 more source

Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing Enterobacterales

Frontiers in Medicine, 2023
Among carbapenem-resistant Enterobacterales, metallo-beta-lactamase producing strains represent a growing therapeutic challenge. While the association of aztreonam and ceftazidime-avibactam has been investigated in recent years for the treatment of ...
Yanis Merad, Anne Conrad, Anne Conrad, Anne Conrad, Anne Conrad, Sophie Brosset, Sophie Brosset, Axel Schmidt, Axel Schmidt, Camille Hanriat, Camille Hanriat, Sebastien Lustig, Sebastien Lustig, Sebastien Lustig, Frederic Laurent, Frederic Laurent, Frederic Laurent, Frederic Laurent, Camille Kolenda, Camille Kolenda, Camille Kolenda, Camille Kolenda, Tiphaine Roussel-Gaillard, Tiphaine Roussel-Gaillard, Tiphaine Roussel-Gaillard, Cecile Batailler, Cecile Batailler, Cecile Batailler, Tristan Ferry, Tristan Ferry, Tristan Ferry, Tristan Ferry, Lyon BJI Study group   +32 more
doaj   +1 more source

In vitro activity of aztreonam–avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019–2021

European Journal of Clinical Microbiology and Infectious Diseases, 2023
This study aimed to report reference method antimicrobial susceptibility results for 24,937 recent (2019–2021) clinical isolates of Enterobacterales from 27 countries in Latin America, Eurasia, Africa/Middle East, and Asia with a focus on the ...
M. Wise, J. Karlowsky, Naglaa Mohamed, S. Kamat, D. Sahm   +4 more
semanticscholar   +1 more source

Successful Treatment of Klebsiella pneumoniae NDM Sepsis and Intestinal Decolonization with Ceftazidime/Avibactam Plus Aztreonam Combination in a Patient with TTP Complicated by SARS-CoV-2 Nosocomial Infection

Medicina, 2021
Carbapenem-resistant Enterobacteriaceae (CRE) are a serious public health threat. Infections due to these organisms are associated with significant morbidity and mortality.
Francesco Perrotta, Marco Paolo Perrini
doaj   +1 more source

Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance [PDF]

, 2020
The rising incidence of bloodstream infections (BSI) due to Gram-negative bacteria (GNB) with difficult-to-treat resistance (DTR) has been recognized as a global emergency. The aim of this review is to provide a comprehensive assessment of the mechanisms
Bassetti, Matteo, Giacobbe, Daniele Roberto, Peghin, Maddalena, Sepulcri, Chiara, Vena, Antonio   +4 more
core   +1 more source

Carbapenem-resistant Klebsiella pneumoniae infections in Chinese children: in vitro activities of ceftazidime-avibactam and aztreonam-avibactam against carbapenemase-producing strains in a two-center study

Frontiers in Cellular and Infection Microbiology
Objective This study assessed epidemiology characteristics, carbapenem-resistance genes, and drug resistance to ceftazidime-avibactam (CZA) and aztreonam-avibactam (AZA) in children with carbapenem-resistant Klebsiella Pneumoniae (CRKP) infections ...
Xiaoping Ran, Xuejun Chen, Cai Wang, Haiping Wang, W. Xie, C. Jing   +5 more
semanticscholar   +1 more source